6.75
-0.44(-6.12%)
Currency In USD
| Previous Close | 7.19 |
| Open | 7.3 |
| Day High | 7.35 |
| Day Low | 6.61 |
| 52-Week High | 8.36 |
| 52-Week Low | 2.2 |
| Volume | 70,313 |
| Average Volume | 1.05M |
| Market Cap | 26.62M |
| PE | -0.7 |
| EPS | -9.67 |
| Moving Average 50 Days | 5.35 |
| Moving Average 200 Days | 3.97 |
| Change | -0.44 |
If you invested $1000 in Athira Pharma, Inc. (ATHA) since IPO date, it would be worth $39.45 as of January 14, 2026 at a share price of $6.75. Whereas If you bought $1000 worth of Athira Pharma, Inc. (ATHA) shares 5 years ago, it would be worth $25.2 as of January 14, 2026 at a share price of $6.75.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA”
GlobeNewswire Inc.
Jan 09, 2026 12:00 PM GMT
New name to reflect recent transformative acquisition of rights to Phase 3 program in metastatic breast cancer and commitment to continued leadership, resilience and innovationBOTHELL, Wash., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (N
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million
GlobeNewswire Inc.
Dec 18, 2025 12:02 PM GMT
Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing Co-Led by Commodore Capital, Perceptive Advisors an
Athira Pharma Announces Reverse Stock Split
GlobeNewswire Inc.
Sep 11, 2025 1:00 PM GMT
BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (“Athira” or “Company”) (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, t
Data not available